spacer
home > ict > winter 2019 > concentration-qt modelling in early phase clinical studies
PUBLICATIONS
International Clinical Trials

Concentration-QT Modelling in Early Phase Clinical Studies

Long QT syndrome is a cardiac side effect that can occur with certain pharmaceuticals. After each beat, the heart repolarises, but, with long QT syndrome, this process does not occur correctly. This can lead to a condition known as Torsadede- point arrhythmia, which can cause irregular heartbeats, fainting, and even sudden death, particularly when the patient is under stress or during exercise.

Once it was understood that drugs can cause long QT syndrome, studying cardiac repolarisation became an important part of the drug development process. Regulators now mandate assessment of whether a new drug has a tendency to prolong the QT interval as part of the clinical development process.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Andreas Lindauer has been a Senior Consultant at SGS Exprimo since 2014. He studied pharmacy at the University of Bonn, Germany, subsequently completing a PhD in clinical pharmacy, focussing on PK/ PD modelling in oncology and the central nervous system.
spacer
Dr Andreas Lindauer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases

MyMD Pharmaceuticals Inc., a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,085,047 titled “Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.”
More info >>

White Papers

Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands

West Pharmaceutical Services, Inc.

The current pharmaceutical market has faced a variety of challenges, including increasing expectations for quality from end-users and regulatory agencies driven by concern for patient safety. While pharmaceutical companies are working to assure that new quality and compliance paradigms are met, a balance must be achieved between the reality of managing costs in an effort to provide a product that meets the requirements of payers along with facilitating profitability in order to continue adequate business reinvestment.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement